Silence Therapeutics PLC Results of EGM (9399T)

TIDMSLN

RNS Number : 9399T

Silence Therapeutics PLC

23 July 2020

Results of General Meeting

London, 23(rd) July 2020

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that at its General Meeting held today, Thursday, 23(rd) July 2020, all resolutions set out in the notice of meeting were duly passed on a poll.

The votes were as follows:

 
 Resolution                Votes        %      Votes against   %     Votes total   % of ISC   Votes withheld 
                            for                                                     voted 
 1 - Restatement 
  of long term 
  incentive plans 
  (ordinary resolution)    38,168,851   98.0   772,001         2.0   38,940,852    47.0       4,276,757 
                          -----------  -----  --------------  ----  ------------  ---------  --------------- 
 2 - Approval 
  of US Employee 
  Sub-Plan (ordinary 
  resolution)              38,185,627   98.1   755,225         1.9   38,940,852    47.0       4,276,757 
                          -----------  -----  --------------  ----  ------------  ---------  --------------- 
 3 - Approval 
  of new articles 
  of association 
  (special resolution)     38,940,642   100    210             0     38,940,852    47.0       4,276,757 
                          -----------  -----  --------------  ----  ------------  ---------  --------------- 
 

The number of the Company's ordinary shares in issue as at the date of the meeting was 82,826,259 ordinary shares of 5p each.

A vote withheld is not a vote in law and has not been counted in the calculation of the proportion of votes for and against the resolutions.

Enquiries:

 
 Silence Therapeutics plc                     Tel: [phone] 
  Iain Ross, Executive Chairman                6900 
  Dr Rob Quinn, Chief Financial Officer 
  Investec Bank plc (Nominated Adviser and     Tel: +44 (0) 20 
   Broker)                                      7597 5970 
   Daniel Adams/Gary Clarence 
 European IR                                  Tel: +44 (0) 20 
  Consilium Strategic Communications           3709 5700 
  Mary-Jane Elliott/Chris Welsh/Angela Gray 
  [e-mail] 
 US IR                                         Tel: [phone] 
  Westwicke Partners 
  Peter Vozzo 
  [e-mail] 
 

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

ROMFLFEEDTIVFII

(END) Dow Jones Newswires

July 23, 2020 12:02 ET (16:02 GMT)